Home LiteratureArticle Details
PMID: 16448708 Published · ppublish English Journal Article

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

Antiviral research ·Vol. 70 ·No. 2 ·2006-06-00 ·Pages 28-38

Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA

Abstract

HCV NS3 protease variants resistant to the protease inhibitor SCH 503034 were selected. Three mutations, T54A, V170A and A156S mutations conferred low to moderate levels of resistance (<20-fold). Longer exposure (>10 passages) or selection with higher levels of compound led to the selection of a more resistant variant, A156T (>100-fold). [Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A., Kwong, A.D., 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279(17), 17508-17514; Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H., Molla, A., 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48(6), 2260-2266.] Combination with IFN-alpha drastically reduced the number of emergent colonies. Resistant colonies showed no change in sensitivity to IFN-alpha. Although the A156T mutation conferred the highest level of resistance to SCH 503034, it significantly reduced the colony formation efficiency (CFE) of the mutant replicon RNA, and rendered replicon cells less fit than those bearing wild-type replicons. Replicon cells bearing mutation A156S were less fit than wild-type in co-culture growth competition assays but showed no impact on CFE. The V170A mutation, on the other hand, did not affect replicon fitness in either assay, which was consistent with its emergence as the dominant mutant after 12 months of continuous selection. The reduced fitness of the most resistant variant suggests that it may be rare in naïve patients and that development of high-level resistance may be slow. Combination therapy with IFN-alpha should also greatly reduce the potential emergence of resistance.

MeSH Terms
Blotting, Western Cell Line, Tumor Drug Resistance, Viral/genetics Enzyme Activation Hepacivirus/drug effects,enzymology,genetics Humans Kinetics Mutagenesis, Site-Directed Mutation Phenotype Proline/analogs & derivatives,pharmacology Protease Inhibitors/pharmacology Protein Binding Protein Processing, Post-Translational Replicon/drug effects,genetics Sequence Analysis Viral Nonstructural Proteins/antagonists & inhibitors,genetics,metabolism
Chemicals
NS3 protein, hepatitis C virus Protease Inhibitors Viral Nonstructural Proteins N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide Proline
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Tong Xiao
Department of Virology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilwoth, NJ 07033, USA. [email protected]
Chase Robert
Skelton Angela
Chen Tong
Wright-Minogue Jackie
Malcolm Bruce A
Article Info
Journal
Antiviral research
Abbr.
Antiviral Res
ISSN
0166-3542
Published
2006-06-00
Epub
2006-00-13
Pages
28-38
Language
English
Region
Netherlands
NLM ID
8109699
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]